全文获取类型
收费全文 | 151422篇 |
免费 | 12877篇 |
国内免费 | 4455篇 |
专业分类
耳鼻咽喉 | 1190篇 |
儿科学 | 2649篇 |
妇产科学 | 1994篇 |
基础医学 | 9143篇 |
口腔科学 | 3246篇 |
临床医学 | 19274篇 |
内科学 | 22068篇 |
皮肤病学 | 2381篇 |
神经病学 | 12591篇 |
特种医学 | 9689篇 |
外国民族医学 | 51篇 |
外科学 | 14132篇 |
综合类 | 21557篇 |
现状与发展 | 24篇 |
一般理论 | 2篇 |
预防医学 | 5663篇 |
眼科学 | 2354篇 |
药学 | 11045篇 |
80篇 | |
中国医学 | 11279篇 |
肿瘤学 | 18342篇 |
出版年
2024年 | 160篇 |
2023年 | 2777篇 |
2022年 | 4053篇 |
2021年 | 6747篇 |
2020年 | 6765篇 |
2019年 | 6186篇 |
2018年 | 5626篇 |
2017年 | 6181篇 |
2016年 | 6395篇 |
2015年 | 6121篇 |
2014年 | 10972篇 |
2013年 | 13182篇 |
2012年 | 8875篇 |
2011年 | 9529篇 |
2010年 | 7856篇 |
2009年 | 7374篇 |
2008年 | 7206篇 |
2007年 | 7564篇 |
2006年 | 6877篇 |
2005年 | 6120篇 |
2004年 | 4912篇 |
2003年 | 4466篇 |
2002年 | 3745篇 |
2001年 | 3222篇 |
2000年 | 2540篇 |
1999年 | 1986篇 |
1998年 | 1586篇 |
1997年 | 1349篇 |
1996年 | 1157篇 |
1995年 | 1139篇 |
1994年 | 933篇 |
1993年 | 702篇 |
1992年 | 581篇 |
1991年 | 525篇 |
1990年 | 432篇 |
1989年 | 387篇 |
1988年 | 368篇 |
1987年 | 309篇 |
1986年 | 244篇 |
1985年 | 290篇 |
1984年 | 248篇 |
1983年 | 186篇 |
1982年 | 182篇 |
1981年 | 171篇 |
1980年 | 139篇 |
1979年 | 130篇 |
1978年 | 70篇 |
1977年 | 44篇 |
1976年 | 53篇 |
1975年 | 33篇 |
排序方式: 共有10000条查询结果,搜索用时 140 毫秒
21.
目的 系统评价翻转课堂教学模式在物理治疗学教学中的应用效果。方法 计算机检索CENTRAL、MEDLINE、EMBASE、CINAHL Plus、Academic Search Premier、Teacher Reference Center、ERIC以及Education Research,纳入翻转课堂教学模式应用于物理治疗学教学的原始研究。检索时限为建库至2021年6月。由2名研究人员独立完成文献筛选、数据提取、质量评价,对翻转课堂教学模式对比传统教学模式在物理治疗学教学中的效果进行综述。结果与结论 共检索文献1 307篇,最终纳入7篇,包括至少770名学生。发表时间集中在2013年至2019年,研究对象为物理治疗学专业学生,主要结局指标为考试成绩。翻转课堂教学模式总体说来可提高学生的笔试成绩,增强高阶思维能力,得到了学生和教师的积极评价。 相似文献
22.
24.
目的 评价多功能套针浮刺疗法对神经根型颈椎病的临床疗效。方法 选取256例神经根型颈椎病患者,按随机数字表法分为观察组与对照组各128例。观察组应用多功能套针浮刺疗法进行干预,对照组为常规针刺治疗。两组患者均治疗7天。分别于治疗前后观察两组患者的简化McGill疼痛问卷(SF-MPQ)、国际标准颈椎功能障碍指数(NDI)和田中靖久颈椎病症状20分法量表评分,并于治疗结束后3个月观察复发率。结果 两组患者治疗后的SF-MPQ量表评分、NDI量表评分及田中靖久颈椎病症状20分法评分与治疗前相比均有改善(P<0.05),且观察组优于对照组(P<0.05);两组患者于治疗后3个月随访,SF-MPQ量表评分与治疗后相比均有改善,且观察组优于对照组(P<0.05);观察组临床疗效总有效率为96.88%,愈显率为81.25%;对照组总有效率为78.13%,愈显率为46.88%,观察组优于对照组(P<0.05)。结论 应用多功能套针浮刺疗法治疗神经根型颈椎病临床疗效显著,见效较快,可有效降低其复发率,且作用稳定,效果持久,值得临床推广应用。 相似文献
25.
26.
27.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
28.
Laura A. Huppert MD Ozge Gumusay MD Dame Idossa MD Hope S. Rugo MD 《CA: a cancer journal for clinicians》2023,73(5):480-515
Hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer is defined by the presence of the estrogen receptor and/or the progesterone receptor and the absence of HER2 gene amplification. HR-positive/HER2-negative breast cancer accounts for 65%–70% of all breast cancers, and incidence increases with increasing age. Treatment varies by stage, and endocrine therapy is the mainstay of treatment in both early stage and late-stage disease. Combinations with cyclin-dependent kinase 4/6 inhibitors have reduced distant recurrence in the early stage setting and improved overall survival in the metastatic setting. Chemotherapy is used based on stage and tumor biology in the early stage setting and after endocrine resistance for advanced disease. New therapies, including novel endocrine agents and antibody-drug conjugates, are now changing the treatment landscape. With the availability of new treatment options, it is important to define the optimal sequence of treatment to maximize clinical benefit while minimizing toxicity. In this review, the authors first discuss the pathologic and molecular features of HR-positive/HER2-negative breast cancer and mechanisms of endocrine resistance. Then, they discuss current and emerging therapies for both early stage and metastatic HR-positive/HER2-negative breast cancer, including treatment algorithms based on current data. 相似文献
29.
Tran Thi Hien Ines Ambite Murphy Lam Yim Wan Michele Cavalera Parisa Esmaeili Arunima Chaudhuri Samudra Sabari Marek Babjuk Catharina Svanborg 《International journal of cancer. Journal international du cancer》2023,153(3):584-599
Bladder cancer is common and one of the most costly cancer forms, due to a lack of curative therapies. Recently, clinical safety and efficacy of the alpha1-oleate complex was demonstrated in a placebo-controlled study of nonmuscle invasive bladder cancer. Our study investigated if long-term therapeutic efficacy is improved by repeated treatment cycles and by combining alpha1-oleate with low-dose chemotherapy. Rapidly growing bladder tumors were treated by intravesical instillation of alpha1-oleate, Epirubicin or Mitomycin C alone or in combination. One treatment cycle arrested tumor growth, with a protective effect lasting at least 4 weeks in mice receiving 8.5 mM of alpha1-oleate alone or 1.7 mM of alpha-oleate combined with Epirubicin or Mitomycin C. Repeated treatment cycles extended protection, defined by a lack of bladder pathology and a virtual absence of bladder cancer-specific gene expression. Synergy with Epirubicin was detected at the lower alpha1-oleate concentration and in vitro, alpha1-oleate was shown to enhance the uptake and nuclear translocation of Epirubicin, by tumor cells. Effects at the chromatin level affecting cell proliferation were further suggested by reduced BrdU incorporation. In addition, alpha1-oleate triggered DNA fragmentation, defined by the TUNEL assay. The results suggest that bladder cancer development may be prevented long-term in the murine model, by alpha1-oleate alone or in combination with low-dose Epirubicin. In addition, the combination of alpha1-oleate and Epirubicin reduced the size of established tumors. Exploring these potent preventive and therapeutic effects will be of immediate interest in patients with bladder cancer. 相似文献
30.
《Journal of vascular and interventional radiology : JVIR》2022,33(6):660-667
PurposeTo investigate the safety and efficacy of an aqueous polyethylene glycol-based liquid embolic agent, Embrace Hydrogel Embolic System (HES), in the treatment of benign and malignant hypervascular tumors.Materials and MethodsA prospective, single-arm, multicenter study included 8 patients, 5 males and 3 females, with a median age of 58.5 years (30–85 years), who underwent embolization in 8 tumors between October 2019 and May 2020. Technical success was defined as successful delivery of HES to the index vessel, with disappearance of >90% of the targeted vascular enhancement or, for portal vein embolization, occlusion of the portal branches to the liver segments for future resection. The volume of HES administered, ease of use (5 point Likert scale), administration time, and adverse events (AEs) were recorded. Evaluation was performed at 7, 30, and 90 days via clinical assessment and blood testing, and follow-up imaging was performed at 30 days.ResultsEight patients were enrolled, and 10 embolizations were performed in 8 lesions. Tumors included hepatocellular carcinoma (n = 4), renal angiomyolipoma (n = 3), and intrahepatic cholangiocarcinoma (n = 1). Technical success was 100%, and the average ease of use was 3.3 ± 1.0 SD. The HES delivery time was 1–28 minutes (median, 16.5 minutes), and the HES volume injected was 0.4–4.0 mL (median, 1.3 mL). All patients reached 30-day follow-up with imaging, and 6 patients reached 90-day follow-up. There were 3 serious AEs in 2 patients that were unrelated to the embolic agent.ConclusionHES resulted in a 100% embolization technical success rate. The product ease of use was acceptable, and no target vessel recanalization was noted on follow-up imaging at 30 days. 相似文献